<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858518</url>
  </required_header>
  <id_info>
    <org_study_id>1408020</org_study_id>
    <secondary_id>2014-A01664-43</secondary_id>
    <nct_id>NCT02858518</nct_id>
  </id_info>
  <brief_title>Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?</brief_title>
  <acronym>PREDIC-AGE</acronym>
  <official_title>Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is a rhythmic cardiac activity disorder disturbing hemodynamic blood
      flow. It is a public health problem with 600,000 to 1 million people involved in France which
      2/3 are aged over 75 years. a FA untreated exposes the patient to a significant risk of
      embolism responsible for a rate stroke (stroke) ischemic estimated at 85%. The anticoagulant
      standard treatment helps prevent the occurrence of this complication.

      However, oral anticoagulation also exposes patients to an increased risk of bleeding. The
      bleeding risk can be assessed using scales: several being proposed (HEMORR2HAGES, HAS-BLED,
      ATRIA and scores Shireman and Charlson ...).

      moreover, in geriatric hospital care, every patient has a &quot;standardized geriatric assessment&quot;
      to assess and quantify functional capacity, autonomy, cognitive abilities, nutritional
      status, psychological state and its environment social.

      Thus, the objective of the investigators study was to determine the frequency of each item of
      each bleeding risk assessment score and geriatric assessment in patients 80 and older
      hospitalized geriatric ward in the department and with anticoagulant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>scale : HEMORR2HAGES</measure>
    <time_frame>at baseline</time_frame>
    <description>hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...</description>
  </primary_outcome>
  <primary_outcome>
    <measure>scale : HAS-Bled</measure>
    <time_frame>at baseline</time_frame>
    <description>arterial hypertension, renal function, liver function, cerebrovascular accident...</description>
  </primary_outcome>
  <primary_outcome>
    <measure>scale : ATRIA</measure>
    <time_frame>at baseline</time_frame>
    <description>anemia, serious kidney diseases, hypertension, antecedent...</description>
  </primary_outcome>
  <primary_outcome>
    <measure>scale : shireman</measure>
    <time_frame>at baseline</time_frame>
    <description>gender, age, hemorrhage, diabetes, anemia...</description>
  </primary_outcome>
  <primary_outcome>
    <measure>scale charlson</measure>
    <time_frame>at baseline</time_frame>
    <description>age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>scale : standardised geriatric assessment</measure>
    <time_frame>at baseline</time_frame>
    <description>comorbidities, cognition, mobility, pain, nutrition, living environment...</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of major bleeding event or not major</measure>
    <time_frame>at baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>genotyping</measure>
    <time_frame>at baseline</time_frame>
    <description>CYP2C9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>genotyping</measure>
    <time_frame>at baseline</time_frame>
    <description>VKCRC1</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Gerontology</condition>
  <arm_group>
    <arm_group_label>patients with atrial fibrillation with anticoagulant treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaires</intervention_name>
    <description>scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)</description>
    <arm_group_label>patients with atrial fibrillation with anticoagulant treatment</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      classical blood sample : NFS, ionograms, CRP, TSH, albumin, vitamin D, Calcium and
      coagulation factors + tube for genetic study
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients seniors with atrial fibrillation with anticoagulant treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hospitalisation in geriatric unit

          -  Atrial fibrillation treated by anticoagulant treatment (AVK or oral anticoagulation)

          -  signed inform consent

        Exclusion Criteria:

          -  estimated lifetime less than 6 months

          -  under guardianship or curatorship

          -  without support person
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie CRAWFORD-ACHOUR, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH de FEURS</name>
      <address>
        <city>Feurs</city>
        <zip>42110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de FIRMINY</name>
      <address>
        <city>Firminy</city>
        <zip>42700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de ROANNE</name>
      <address>
        <city>Roanne</city>
        <zip>42300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de SAINT-CHAMOND</name>
      <address>
        <city>Saint-chamond</city>
        <zip>42400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anticoagulant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

